tbuckley/cabot-search huggingface dataset:
CD4+ follicular regulatory T cells optimize the influenza virus–specific B cell response
Authors: Yisi Lu, Roy Jiang, Alec W. Freyn, Jiawei Wang, Shirin Strohmeier, Katlyn Lederer, Michela Locci, Hongyu Zhao, Davide Angeletti, Kevin C. O’Connor, Steven H. Kleinstein, Raffael Nachbagauer, Joe Craft
Journal: The Journal of Experimental Medicine (2020)

CD4+ follicular regulatory T (Tfr) cells control B cell responses through the modulation of follicular helper T (Tfh) cells and germinal center development while suppressing autoreactivity; however, their role in the regulation of productive germinal center B cell responses and humoral memory is incompletely defined. We show that Tfr cells promote antigen-specific germinal center B cell responses upon influenza virus infection. Following viral challenge, we found that Tfr cells are necessary for robust generation of virus-specific, long-lived plasma cells, antibody production against both hemagglutinin (HA) and neuraminidase (NA), the two major influenza virus glycoproteins, and appropriate regulation of the BCR repertoire. To further investigate the functional relevance of Tfr cells during viral challenge, we used a sequential immunization model with repeated exposure of antigenically partially conserved strains of influenza viruses, revealing that Tfr cells promote recall antibody responses against the conserved HA stalk region. Thus, Tfr cells promote antigen-specific B cell responses and are essential for the development of long-term humoral memory.
Abstract 11269: High-dose vs. Low-dose Ivig For Kawasaki Disease Children With a Weight of 25kg or More
Authors: Takanori Suzuki, Nobuaki Michihata
Journal: Circulation (2019)

Introduction: Kawasaki Disease (KD) mainly affects children under six years of age. The most recommended treatment is intravenous immunoglobulin (IVIG) at 2g/kg. However, older children with higher...
Autism Spectrum Disorder Genetics and the Search for Pathological Mechanisms
Authors: Devanand S. Manoli, Matthew W. State
Journal: American Journal of Psychiatry (2021)

Recent progress in the identification of genes and genomic regions contributing to autism spectrum disorder (ASD) has had a broad impact on our understanding of the nature of genetic risk for a range of psychiatric disorders, on our understanding of ASD biology, and on defining the key challenges now facing the field in efforts to translate gene discovery into an actionable understanding of pathology. While these advances have not yet had a transformative impact on clinical practice, there is nonetheless cause for real optimism: reliable lists of risk genes are large and growing rapidly; the identified encoded proteins have already begun to point to a relatively small number of areas of biology, where parallel advances in neuroscience and functional genomics are yielding profound insights; there is strong evidence pointing to mid-fetal prefrontal cortical development as one nexus of vulnerability for some of the largest-effect ASD risk genes; and there are multiple plausible paths forward toward rational therapeutics development that, while admittedly challenging, constitute fundamental departures from what was possible prior to the era of successful gene discovery.
Laparoscopic Lavage vs Resection for Purulent Diverticulitis
Authors: Kellie E. Cunningham, Brian S. Zuckerbraun
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
<b>Germline Cancer Predisposition Variants in</b> <b>Pediatric Rhabdomyosarcoma: A Report From the Children’s Oncology Group</b>
Authors: He Li, Saumya D Sisoudiya, Bailey A Martin-Giacalone, Michael M Khayat, Shannon Dugan-Perez, Deborah A Marquez-Do, Michael E Scheurer, Donna Muzny, Eric Boerwinkle, Richard A Gibbs, Yueh-Yun Chi, Donald A Barkauskas, Tammy Lo, David Hall, Douglas R Stewart, Joshua D Schiffman, Stephen X Skapek, Douglas S Hawkins, Sharon E Plon, Aniko Sabo, Philip J Lupo
Journal: JNCI Journal of the National Cancer Institute (2020)

Several cancer-susceptibility syndromes are reported to underlie pediatric rhabdomyosarcoma (RMS); however, to our knowledge there have been no systematic efforts to characterize the heterogeneous genetic etiologies of this often-fatal malignancy.We performed exome-sequencing on germline DNA from 615 patients with newly diagnosed RMS consented through the Children's Oncology Group. We compared the prevalence of cancer predisposition variants in 63 autosomal-dominant cancer predisposition genes in these patients with population controls (n = 9963). All statistical tests were 2-sided.We identified germline cancer predisposition variants in 45 RMS patients (7.3%; all FOXO1 fusion negative) across 15 autosomal dominant genes, which was statistically significantly enriched compared with controls (1.4%, P = 1.3 × 10-22). Specifically, 73.3% of the predisposition variants were found in predisposition syndrome genes previously associated with pediatric RMS risk, such as Li-Fraumeni syndrome (TP53) and neurofibromatosis type I (NF1). Notably, 5 patients had well-described oncogenic missense variants in HRAS (p.G12V and p.G12S) associated with Costello syndrome. Also, genetic etiology differed with histology, as germline variants were more frequent in embryonal vs alveolar RMS patients (10.0% vs 3.0%, P = .02). Although patients with a cancer predisposition variant tended to be younger at diagnosis (P = 9.9 × 10-4), 40.0% of germline variants were identified in those older than 3 years of age, which is in contrast to current genetic testing recommendations based on early age at diagnosis.These findings demonstrate that genetic risk of RMS results from germline predisposition variants associated with a wide spectrum of cancer susceptibility syndromes. Germline genetic testing for children with RMS should be informed by RMS subtypes and not be limited to only young patients.
Abstract 14131: Propionic Acidemia as a Cause of Adult-onset Dilated Cardiomyopathy
Authors: Apollonia Helderman-vd Enden, Moniek Riemersma, Mark R Hazebroek, Gajja S Salomons, Sacha Ferdinandusse, Martijn C Brouwers, Liesbeth M van der Ploeg, Stephane R Heymans, Jan F Glatz, Arthur van den Wijngaard, Ingrid P Krapels, Jörgen Bierau, Han G Brunner
Journal: Circulation (2017)

Introduction: Dilated cardiomyopathy (DCM) is extremely heterogeneous with a large proportion due to dominantly inherited disease-causing variants in sarcomeric genes. Recessive metabolic diseases ...
Kidney Transplantation in the United States During the Coronavirus Disease 2019 Pandemic: An Interrupted Time Series Analysis
Authors: Ekamol Tantisattamo, Natnicha Leelaviwat, Sakditad Saowapa, Natchaya Polpichai, Busara Songtanin, Possawat Vutthikraivit, Chawit Lopimpisuth
Journal: Journal of the American Society of Nephrology (2020)

Background: The number of kidney transplant (KT) in the United States (US) has decreased during COVID-19 pandemic;however, the magnitude of this impact is unclear  Methods: A period from January 5 to April 18, 2020 was divided into pre- and post- COVID-19 periods by assigning March 1, 2020 as the first day of the post-COVID-19 outbreak in the US  The number of waitlist candidates (WLC) and new KT every 7 days were obtained from OPTN/SRTR  An interrupted time series analysis was performed to examine an incidence rate ratio (IRR) between pre- and post-COVID-19 period by using multiple Poisson regression  Results: Compared to pre-COVID-19 period, the average number of new KT during post-COVID-19 period decreased (479±33 vs 318±119 cases/week, mean difference±SEM 161±44, 95%CI 67, 255)  The number of WLC was relatively stable (mean±SD 65,937±959 cases/week);whereas, it decreased during post-COVID-19 period (61,759±2203 cases/week)  Mean incidence rates (IR) of new KT during pre- and post-COVID-19 periods were 727±58 and 511±176 cases/105 WLC-week, respectively (Figure1)  The IR of new KT during post-COVID-19 period was 29% lower than those during pre-COVID-19 period(IRR 0 71, 95%CI 1 96, 2 11) and each one additional week was associated with a 4% decrease in the new KT (IRR 0 96, 95%CI 2 60, 2 63)  After adjusted by age group, transplant areas, and time-study period interaction term, the IR of new KT was 3% increase for every one more week during pre-COVID-19 period (IRR 1 03);whereas, there were 12% decrease for every one more week after March 1, 2020(IRR 0 88)  Compared to pre-COVID-19 period, the IR of new KT during post- COVID-19 period was 9% lower for every additional week for each corresponding period (IRR 0 91)  Conclusions: COVID-19 outbreak in the US since March 2020 is an independent factor of a significant decline in the number of new KT  Further information regarding ability of control COVID-19 may direct KT
Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement
Authors: Andrea S. Gershon, Peter K. Lindenauer, Kevin C. Wilson, Louise Rose, Allan J. Walkey, Mohsen Sadatsafavi, Kevin J. Anstrom, David H. Au, Bruce G. Bender, M. Alan Brookhart, Raed A. Dweik, MeiLan K. Han, Min J. Joo, Valery Lavergne, Anuj B. Mehta, Marc Miravitlles, Richard A. Mularski, Nicolas Roche, Eyal Oren, Kristin A. Riekert, Noah C. Schoenberg, Therese A. Stukel, Curtis H. Weiss, Hannah Wunsch, Joel J. Africk, Jerry A. Krishnan
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsResultsConclusionsReferencesCITING ARTICLES
Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies
Authors: J Whang-Peng, T Knutsen, ES Jaffe, SM Steinberg, M Raffeld, WP Zhao, P Duffey, K Condron, T Yano, DL Longo
Journal: Blood (1995)
Association of periodontitis with markers of immunologic and haemostatic state in people living with HIV
Authors: Hester Groenewegen, Jaime F. Borjas-Howard, Konstantina Delli, Karina Meijer, Arjan Vissink, Frederik K.L. Spijkervet, Annechien J.A. Lambeck, Wouter F.W. Bierman
Journal: Journal of Infection (2020)
<i>‘None of my providers have the slightest clue what to do with me’:</i> Transmasculine individuals’ experiences with gynecological healthcare providers
Authors: Lex Pulice-Farrow, Kirsten A. Gonzalez, Louis Lindley
Journal: International Journal of Transgender Health (2020)

Background: Transgender individuals experience barriers to accessing healthcare including financial difficulties, lack of insurance, and discrimination and victimization by medical providers. Transmasculine patients face unique challenges and are more at risk for reproductive pathology resulting from a lack of regular gynecological care. Presently, a dearth of research exists on the needs of transmasculine patients in gynecological healthcare settings. While the literature on experiences of transmasculine individuals has focused on physical health and risk factors for this population, this study focuses on the information that transmasculine individuals want their gynecologists to know when working with trans patients. Aim: The aim of the present study was to explore the lived experiences of transmasculine individuals in order to understand what they feel their medical providers need to know about their experiences seeking gynecological care. Method: Participants included 167 adults who identified as masculine of center or trans men ranging in age from 18 - 56 (M = 27.99, SD = 6.06). Participants completed an online survey and responded to open-ended questions about their gynecological healthcare experiences. Qualitative responses were analyzed via thematic analysis. Results: Results revealed four information-salient themes, including: 1) Patient comfort levels; 2) Language; 3) Provider assumptions; and 4) Provider knowledge. Conclusions: Findings suggest that gynecologists are key in both exacerbating barriers and creating more affirming spaces for transmasculine patients. Discussion of the results focuses on the ways that providers can improve the gynecologic healthcare experiences of their transmasculine patients.
Protein Intake and Cause-Specific Mortality
Authors: Zhengyu Ren, William Kwame Amakye, Maojin Yao
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Incidence of New-Onset Proteinuria in AKI Associated with COVID-19 Is Not Greater Than It Is in AKI from Other Causes
Authors: Vipin Varghese, Muner Mohamed, Juan Carlos Q. Velez
Journal: Journal of the American Society of Nephrology (2020)

Background: Early reports of acute kidney injury (AKI) associated with COVID-19 have claimed high incidence of proteinuria  If so, it may suggest an AKI pathogenesis not solely related to ischemic acute tubular injury (ATI)  We hypothesized that those claims result from observation bias  Therefore, we sought to investigate the rate of De novo proteinuria in AKI associated with COVID-19 (CoV-AKI) compared to that of AKI in the pre-COVID-19 era (non-CoV-AKI)  Methods: Hospitalized patients with CoV-AKI entered the cohort (n=161)  As a control non-CoV-AKI group (n=186), we accessed a database of patients with AKI who underwent urinary sediment microscopy due to suspicion of an intrinsic cause of AKI (Sedi-AKI cohort, 2017-2019)  We examined the incidence of proteinuria of any degree (1+ dipstick), significant [urine protein-to-creatinine ratio (UPCR) ≥ 0 5-3 0 g/g or 2+ dipstick] or overt [UPCR ≥ 3 0 g/g + 3+ dipstick]  Results: Median age were similar: 65 (34-95) and 60 (20-88) years for CoV-AKI and non-CoV-AKI, respectively  Women were 62% and 63% (p=0 86)  Black race was more common in CoV-AKI (75% vs  35%;p=<0 0001)  ATI (ischemic and/or toxic) was the presumed cause of AKI in 75% and 71% of CoV-AKI and non-CoV-AKI, respectively  Incidence of any, significant or overt proteinuria were 123/148 (83%) vs  127/184 (69%) (p=0 003), 98/148 (66%) vs  81/184 (44%) (p=0 0001) and 14/148 (10%) vs  23/184 (13%) (p=0 39), for CoV-AKI and non-CoV-AKI, respectively  Among those with significant proteinuria, no difference in median UPCR was found [0 69 vs  0 69 g/g (p=0 23)]  Using baseline UPCR when available, rates of De novo significant and overt proteinuria were similar [57/124 (46%) vs 57/123 (46%) (p=1 00) and 6/124 (5%) vs 7/123 (7%) (p=0 75)]  Among overt cases who underwent kidney biopsy, collapsing glomerulopathy was found in 3/4 (75%) in the CoV-AKI group compared to 0/11 (0%) in the control (p=0 002)  Conclusions: The incidence rate of new onset proteinuria was not found to be increased in CoV-AKI and is consistent with that of other forms of ATI  An observed overall greater incidence in significant proteinuria in CoV-AKI may be driven by preexisting proteinuria  While the rate of overt proteinuria is not greater in CoV-AKI, the primary cause of De novo glomerular disease may vary
The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients
Authors: Marina Martello, Rosalinda Termini, Barbara Santacroce, Enrica Borsi, Vincenza Solli, Andrea Poletti, Chiara Benni, Lucia Pantani, Serena Rocchi, Elena Zamagni, Paola Tacchetti, Beatrice Zannetti, Francesca Ulbar, Mario Arpinati, Gabriella Chirumbolo, Nicoletta Testoni, Giulia Marzocchi, Gaia Ameli, Giovanni Martinelli, Michele Cavo, Carolina Terragna
Journal: Blood (2017)
화농성 간농양의 원인균 및 치료의 최근 변화
Authors: 나병규 ( Na Byeonggyu ), 김연수 ( Kim Yeonsu ), 문희석 ( Mun Huiseog ), 박기오 ( Park Gio ), 김선문 ( Kim Seonmun ), 이엄석 ( Lee Eomseog ), 양현웅 ( Yang Hyeonung ), 서승원 ( Seo Seungwon ), 김석현 ( Kim Seoghyeon ), 이병석 ( Lee Byeongseog ), 김남재 ( Kim Namjae ), 이헌영 ( Lee)
Journal: Clinical and Molecular Hepatology (2003)

목적: 최근의 간농양 환자들의 임상상, 원인 및 치료에 대해 분석하여 기존의 보고와 비교함으로써 변화의 유무를 보고자 하였다. 대상과 방법: 1996년 3월부터 2001년 9월까지 5년간 본원에 입원하여 화농성 간농양으로 치료를 받은 94예를 대상으로 연령, 성별, 증상, 신체검사 소견, 검사실 소견, 세균학적 검사, 동반질환, 감염경로, 농양의 특징, 치료법, 합병증 및 예후 등을 분석하였다. 결과: 평균 연령은 60?4세였으며 남자가 55명 여자가 39명으로 남녀 비는 1.4:1이었다. 남자에서는 50대에서 가장 많이 발생했으며 여자인 경우는 60대에서 빈도가 가장 높았다. 임상증상은 발열(79.8%), 오한(43.6%)이 신체검사 소견으로 발열(53.2%), 상복부 압통(44.7%)이 흔하였다. 농양이 단발성인 경우가 85.1%이었고. 우엽에만 있었던 경우가 70.3%이었다. 84예 중 67예에서 배양이 되어서 78.8%의 양성율을 보였고 단일 균주였으며 Klebsiella pneumoniae 44예(65.7%), E. coli 11예(16.4%)였다. 동반질환은 당뇨병이 14예, 악성 종양이 10예(간담도계 7예, 간세포암 2예, 직장암 1예), 담낭 절제술을 시행 받았던 예가 2예, 간경변증 1예, 만성 신부전 1예, 다낭성 신증 1예 및 막성 사구체 신염 1예였다. 원인을 찾지 못했던 예가 70예(74.5%)로 가장 흔하였으며, 상행성 전파가 20예(21.3%), 혈행성 3예(3.2%) 및 직접 전파된 경우가 1예(1.1%)였다. 경피적 배액술을 시행한 경우가 69예(73.4%), 경피적 흡인술을 시행한 경우는 15예(16.0%), 경피적 배액술과 경피적 흡인술을 같이 시행한 경우는 2예(2.1%), 항생제 치료만을 시행한 8예(8.5%)였다. 경피적 배액술을 시행한 예중 6예(8.7%), 경피적 흡인술을 시행한 예중 2예(13.3%), 항생제만 쓴 경우는 1예(1.3%), 총 9예(9.6%)에서 사망 또는 가망이 없어서 퇴원하였다. 호흡기 합병증이 23예(24.5%)로 가장 흔하였고 급성 신부전이 4예, 복막염은 3예, 농양의 파열이 2예, 치료적 시술이 필요한 답즙낭 발생이 2예 및 횡격막하 농양의 발생이 1예에서 있었다. 결론: 최근의 화농성 간농양에서 Klebsiella pneumoniae가 가장 흔한 균이며 일차적인 치료로는 경피적 배농술(경피적 도관 배액술, 경피적 흡인 천자)을 선택할 수 있을 것으로 판단된다.
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Authors: Alexey Berezhnoy, Bradley J. Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu, Jonathan Li, Su-Shin Hao, Anushka De Costa, Sanjeev Kaul, Johanna Bendell, Gregory M. Cote, Jason J. Luke, Rachel E. Sanborn, Manish R. Sharma, Francine Chen, Hua Li, Gundo Diedrich, Ezio Bonvini, Paul A. Moore
Journal: Cell Reports Medicine (2020)

Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the observation that PD-1 and CTLA-4 are co-expressed by tumor-infiltrating lymphocytes, an investigational PD-1 x CTLA-4 bispecific DART molecule, MGD019, is engineered to maximize checkpoint blockade in the tumor microenvironment via enhanced CTLA-4 blockade in a PD-1-binding-dependent manner. In vitro, MGD019 mediates the combinatorial blockade of PD-1 and CTLA-4, confirming dual inhibition via a single molecule. MGD019 is well tolerated in non-human primates, with evidence of both PD-1 and CTLA-4 blockade, including increases in Ki67+CD8 and ICOS+CD4 T cells, respectively. In the ongoing MGD019 first-in-human study enrolling patients with advanced solid tumors (NCT03761017), an analysis undertaken following the dose escalation phase revealed acceptable safety, pharmacodynamic evidence of combinatorial blockade, and objective responses in multiple tumor types typically unresponsive to checkpoint inhibitor therapy.
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Authors: Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, Victoria C. Yan, Yasaman Barekatain, Sunada Khadka, Jeffrey J. Ackroyd, Dimitra K. Georgiou, Cong-Dat Pham, Kenisha Arthur, David Maxwell, Zhenghong Peng, Paul G. Leonard, Barbara Czako, Federica Pisaneschi, Pijus Mandal, Yuting Sun, Rafal Zielinski, Susana Castro Pando, Xiaobo Wang, Theresa Tran, Quanyu Xu, Qi Wu, Yongying Jiang, Zhijun Kang, John M. Asara, Waldemar Priebe, William Bornmann, Joseph R. Marszalek, Ronald A. DePinho, Florian L. Muller
Journal: Nature Metabolism (2020)
Tick peptides evoke itch by activating MrgprC11/MRGPRX1 to sensitize TRPV1 in pruriceptors
Authors: Xueke Li, Haifeng Yang, Yuewen Han, Shijin Yin, Bingzheng Shen, Yingliang Wu, Wenxin Li, Zhijian Cao
Journal: Journal of Allergy and Clinical Immunology (2020)

Tick bites severely threaten human health because they allow the transmission of many deadly pathogens, including viruses, bacteria, protozoa, and helminths. Pruritus is a leading symptom of tick bites, but its molecular and neural bases remain elusive.This study sought to discover potent drugs and targets for the specific prevention and treatment of tick bite-induced pruritus and arthropod-related itch.We used live-cell calcium imaging, patch-clamp recordings, and genetic ablation and evaluated mouse behavior to investigate the molecular and neural bases of tick bite-induced pruritus.We found that 2 tick salivary peptides, IP defensin 1 (IPDef1) and IR defensin 2 (IRDef2), induced itch in mice. IPDef1 was further revealed to have a stronger pruritogenic potential than IRDef2 and to induce pruritus in a histamine-independent manner. IPDef1 evoked itch by activating mouse MrgprC11 and human MRGPRX1 on dorsal root ganglion neurons. IPDef1-activated MrgprC11/X1 signaling sensitized downstream ion channel TRPV1 on dorsal root ganglion neurons. Moreover, IPDef1 also activated mouse MrgprB2 and its ortholog human MRGPRX2 selectively expressed on mast cells, inducing the release of inflammatory cytokines and driving acute inflammation in mice, although mast cell activation did not contribute to oxidated IPDef1-induced itch.Our study identifies tick salivary peptides as a new class of pruritogens that initiate itch through MrgprC11/X1-TRPV1 signaling in pruritoceptors. Our work will provide potential drug targets for the prevention and treatment of pruritus induced by the bites or stings of tick and maybe other arthropods.
Quantitative PET Measurements of Myocardial Blood Flow in Young, Healthy Volunteers: What Should We Expect?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Henry Gewirtz
Journal: JACC. Cardiovascular imaging (2011)
Risk Factors for AKI in Patients Hospitalized with COVID-19
Authors: Mridula Nadamuni, Yu-Lun Liu, Sadaf S. Khan, Shani Shastri, Duwayne L. Willett, Nilum Rajora, Catherine Chen, Susan Hedayati
Journal: Journal of the American Society of Nephrology (2020)

Nadamuni, Mridula; Liu, Yu-Lun; Khan, Sadaf S.; Shastri, Shani; Willett, Duwayne L.; Rajora, Nilum; Chen, Catherine; Hedayati, Susan Author Information